[1]Wang Kai-Chen., Tsai Ching-Piao., Lee Chao-Lin., Chen Shao-Yuan., Chen Shyi-Jou.(2011). The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan. Eur Neurol, 65(2), 99-104. doi:10.1159/000322740
[2]Ochi Hirofumi., Fujihara Kazuo.(2016). Demyelinating diseases in Asia. Curr Opin Neurol, 29(3), 222-8. doi:10.1097/WCO.0000000000000328
[3]Houzen Hideki,,Kondo Kimito,,Niino Masaaki,... & Tanaka Keiko.(2017).Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.. Neurology(19), doi:10.1212/WNL.0000000000004611.
[4]Fang Chen-Wen., Wang Hsin-Pei., Chen Ho-Min., Lin Jou-Wei., Lin Wei-Sheng.(2020). Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015. Mult Scler Relat Disord, 45(undefined), 102425. doi:10.1016/j.msard.2020.102425
[5]Shosha Eslam., Dubey Divyanshu., Palace Jacqueline., Nakashima Ichiro., Jacob Anu., Fujihara Kazuo., Takahashi Toshiyuki., Whittam Daniel., Leite Maria Isabel., Misu Tatsuro., Yoshiki Takai., Messina Silvia., Elsone Liene., Majed Masoud., Flanagan Eoin., Gadoth Avi., Huebert Carey., Sagen Jessica., Greenberg Benjamin M., Levy Michael., Banerjee Aditya., Weinshenker Brian., Pittock Sean J.(2018). Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology, 91(17), e1642-e1651. doi:10.1212/WNL.0000000000006392
[6]Qiu Yuhan., Zhou Qiao., Du Qin., Chen Hongxi., Shi Ziyan., Zhang Ying., Wang Jiancheng., Yan Chao., Zhao Zhengyang., Yang Mu., Zhou Hongyu.(2020). Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China. J Neuroimmunol, 347(undefined), 577351. doi:10.1016/j.jneuroim.2020.577351
[7] Papp Viktoria., Magyari Melinda., Aktas Orhan., Berger Thomas., Broadley Simon A., Cabre Philippe., Jacob Anu., Kira Jun-Ichi., Leite Maria Isabel., Marignier Romain., Miyamoto Katsuichi., Palace Jacqueline., Saiz Albert., Sepulveda Maria., Sveinsson Olafur., Illes Zsolt.(2021). Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology, 96(2), 59-77. doi:10.1212/WNL.0000000000011153
[8]Popescu B F Gh., Lennon V A., Parisi J E., Howe C L., Weigand S D., Cabrera-Gómez J A., Newell K., Mandler R N., Pittock S J., Weinshenker B G., Lucchinetti C F.(2011). Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology, 76(14), 1229-37. doi:10.1212/WNL.0b013e318214332c
[9]Pittock Sean J., Weinshenker Brian G., Lucchinetti Claudia F., Wingerchuk Dean M., Corboy John R., Lennon Vanda A.(2006). Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol, 63(7), 964-8. doi:10.1001/archneur.63.7.964
[10]Camara-Lemarroy Carlos R., Burton Jodie M.(2019). Area postrema syndrome: A short history of a pearl in demyelinating diseases. Mult Scler, 25(3), 325-329. doi:10.1177/1352458518813105
[11]Seok Jin Myoung., Cho Hye-Jin., Ahn Suk-Won., Cho Eun Bin., Park Min Su., Joo In-Soo., Shin Ha Young., Kim Sun-Young., Kim Byung-Jo., Kim Jong Kuk., Cho Joong-Yang., Huh So-Young., Kwon Ohyun., Lee Kwang-Ho., Kim Byoung Joon., Min Ju-Hong.(2017). Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. Mult Scler, 23(13), 1748-1756. doi:10.1177/1352458516685416
[12]Zhang Lin-Jie., Yang Li-Na., Li Ting., Wang Jing., Qi Yuan., Zhang Da-Qi., Yang Chun-Sheng., Yang Li.(2017). Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. Int J Neurosci, 127(4), 334-338. doi:10.1080/00207454.2016.1254630
[13]Liang Jie., Liu Jia., Gu Meifeng., Zhu Cansheng., Xu Xiaofeng., Fan Rong., Peng Fuhua., Jiang Ying.(2021). Clinical Characteristics of Chinese Male Patients with Aquaporin-4 Antibody-Positive Late-Onset Neuromyelitis Optica Spectrum Disorder. Neuroimmunomodulation, 28(2), 61-67. doi:10.1159/000515555
[14]Wingerchuk Dean M., Banwell Brenda., Bennett Jeffrey L., Cabre Philippe., Carroll William., Chitnis Tanuja., de Seze Jérôme., Fujihara Kazuo., Greenberg Benjamin., Jacob Anu., Jarius Sven., Lana-Peixoto Marco., Levy Michael., Simon Jack H., Tenembaum Silvia., Traboulsee Anthony L., Waters Patrick., Wellik Kay E., Weinshenker Brian G., International Panel for NMO Diagnosis.(2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177-89. doi:10.1212/WNL.0000000000001729
[15] Hyun Jae-Won., Kwon Young Nam., Kim Sung-Min., Lee Hye Lim., Jeong Woo Kyo., Lee Hye Jung., Kim Byoung Joon., Kim Seung Woo., Shin Ha Young., Shin Hyun-June., Oh Sun-Young., Huh So-Young., Kim Woojun., Park Min Su., Oh Jeeyoung., Jang Hyunmin., Park Na Young., Lee Min Young., Kim Su-Hyun., Kim Ho Jin.(2020). Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies. Front Neurol, 11(undefined), 396. doi:10.3389/fneur.2020.00396
[16]Du Qin., Shi Ziyan., Chen Hongxi., Zhang Ying., Wang Jiancheng., Qiu Yuhan., Zhao Zhengyang., Zhang Qin., Zhou Hongyu.(2021). Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders. J Neuroimmunol, 353(undefined), 577494. doi:10.1016/j.jneuroim.2021.577494
[17]Zhou Chenguang., He Yuanhong., Gao Xiaoya., Zhu Yinghui., Chao Zhiwen., Wang Xingping.(2018). Neuromyelitis optical spectrum disorders presenting with isolated "inverted V" sign in area postrema. Neurol Sci, 39(7), 1299-1301. doi:10.1007/s10072-018-3302-9
[18]Zhou C., Liao L., Sun R., Wang J., Di W., Zhu Y., He Y.(2021). Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: A retrospective study. Rev Neurol (Paris), 177(4), 400-406. doi:10.1016/j.neurol.2020.07.019
[19]Martín-Nares E., Hernandez-Molina G., Fragoso-Loyo H.(2019). Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus, 28(11), 1302-1311. doi:10.1177/0961203319877255
[20]Chang Haoxiao., Cong Hengri., Wang Huabing., Du Li., Tian De-Cai., Ma Yuetao., Xu Yun., Wang Yupeng., Yin Linlin., Zhang Xinghu.(2021). Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder. Front Immunol, 12(undefined), 645277. doi:10.3389/fimmu.2021.645277
[21]Lee Eun-Jae., Lim Young-Min., Kim Sun-Young., Lee JooKyung., Kim Hyunjin., Jin Joo Yea., Oh Yeo Jin., Kim Kwang-Kuk.(2019). The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder. J Neuroimmunol, 328(undefined), 1-4. doi:10.1016/j.jneuroim.2018.11.012
[22]Lin Jie., Xue Binbin., Zhu Ruofan., Pan Juyuan., Li Jia., Lin Yan., Li Xiang., Xia Junhui.(2021). Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci, undefined(undefined), undefined. doi:10.1007/s10072-021-05079-4
[23]Li Rui., Wang Jingqi., Li Cong., Liu Xiangfu., Chu Muyang., Chang Yanyu., Wang Yuge., Wang Xia., Yu Boguang., Ling Li., Yang Hui., Yang Huan., Hu Xueqiang., Qiu Wei.(2021). Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone. J Neuroimmunol, 356(undefined), 577604. doi:10.1016/j.jneuroim.2021.577604
[24]Li Xindi., Tian De-Cai., Fan Moli., Xiu Yuwen., Wang Xinli., Li Ting., Jia Dongmei., Xu Wangshu., Song Tian., Shi Fu-Dong., Zhang Xinghu.(2020). Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord, 44(undefined), 102325. doi:10.1016/j.msard.2020.102325
[25]Kim Su-Hyun., Kim Woojun., Li Xue Feng., Jung In-Ja., Kim Ho Jin.(2011). Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol, 68(11), 1412-20. doi:10.1001/archneurol.2011.154
[26]Mealy Maureen A., Wingerchuk Dean M., Palace Jacqueline., Greenberg Benjamin M., Levy Michael.(2014). Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol, 71(3), 324-30. doi:10.1001/jamaneurol.2013.5699
[27]Novi Giovanni., Bovis Francesca., Capobianco Marco., Frau Jessica., Mataluni Giorgia., Curti Erica., Zuliani Luigi., Cavalla Paola., Brambilla Laura., Annovazzi Pietro., Repice Anna Maria., Lanzillo Roberta., Esposito Sabrina., Benedetti Luana., Maietta Ilaria., Sica Francesco., Buttari Fabio., Malucchi Simona., Fenu Giuseppe., Landi Doriana., Bosa Chiara., Realmuto Sabrina., Malentacchi Maria., Granella Franco., Signori Alessio., Bonavita Simona., Uccelli Antonio., Sormani Maria Pia., iMUST group.(2019). Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord, 36(undefined), 101430. doi:10.1016/j.msard.2019.101430
[28]Wang Yupeng., Chang Haoxiao., Zhang Xinghu., Yin Linlin.(2021). Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Mult Scler Relat Disord, 50(undefined), 102843. doi:10.1016/j.msard.2021.102843
[29]Zhang Meini., Zhang Chuntao., Bai Peng., Xue Huiru., Wang Guilian.(2017). Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg, 117(3), 695-702. doi:10.1007/s13760-017-0795-6
[30]Shi Bingxin., Zhao Mangsuo., Qiao Liyan., Huang Fangjie., Zhou Shimei., Wei Yan., Wang Jing., Wang Ning.(2021). Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord, 54(undefined), 103143. doi:10.1016/j.msard.2021.103143
[31]Maurer Michael A., Tuller Friederike., Gredler Viktoria., Berger Thomas., Lutterotti Andreas., Lünemann Jan D., Reindl Markus.(2016). Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination. J Neuroimmunol, 290(undefined), 49-53. doi:10.1016/j.jneuroim.2015.11.006
[32]Du Qin., Shi Ziyan., Chen Hongxi., Zhang Ying., Wang Jiancheng., Qiu Yuhan., Zhao Zhengyang., Zhang Qin., Zhou Hongyu.(2021). Mortality of neuromyelitis optica spectrum disorders in a Chinese population. Ann Clin Transl Neurol, 8(7), 1471-1479. doi:10.1002/acn3.51404
[33]Kim Su-Hyun., Jang Hyunmin., Park Na Young., Kim Yeseul., Kim So-Yeon., Lee Min Young., Hyun Jae-Won., Kim Ho Jin.(2021). Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol Neuroinflamm, 8(2), undefined. doi:10.1212/NXI.0000000000000947
[34]Li Cong., Wang Jingqi., Sun Xiaobo., Li Rui., Chang Yanyu., Wang Yuge., Zhong Xiaonan., Kermode Allan G., Mao Zhifeng., Qiu Wei.(2021). The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China. J Neuroimmunol, 353(undefined), 577506. doi:10.1016/j.jneuroim.2021.577506
[35]Schindler Patrick., Grittner Ulrike., Oechtering Johanna., Leppert David., Siebert Nadja., Duchow Ankelien S., Oertel Frederike C., Asseyer Susanna., Kuchling Joseph., Zimmermann Hanna G., Brandt Alexander U., Benkert Pascal., Reindl Markus., Jarius Sven., Paul Friedemann., Bellmann-Strobl Judith., Kuhle Jens., Ruprecht Klemens.(2021). Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation, 18(1), 105. doi:10.1186/s12974-021-02138-7
[36]Wang Jingqi., Cui Chunping., Lu Yaxin., Chang Yanyu., Wang Yuge., Li Rui., Shan Yilong., Sun Xiaobo., Long Youming., Wang Honghao., Wang Zhanhang., Lee Michael., He Shane., Lu Zhengqi., Qiu Wei., Tan Sha.(2021). Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. Front Immunol, 12(undefined), 720907. doi:10.3389/fimmu.2021.720907
[37]Li Rui., Wang Jingqi., Li Cong., Liu Xiangfu., Chu Muyang., Chang Yanyu., Wang Yuge., Wang Xia., Yu Boguang., Ling Li., Yang Hui., Yang Huan., Hu Xueqiang., Qiu Wei.(2021). Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone. J Neuroimmunol, 356(undefined), 577604. doi:10.1016/j.jneuroim.2021.577604
[38]Wei Yuzhen., Chang Haoxiao., Li Xindi., Wang Huabing., Du Li., Zhou Heng., Xu Wangshu., Ma Yuetao., Yin Linlin., Zhang Xinghu.(2018). Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6. Neuroimmunomodulation, 25(4), 215-224. doi:10.1159/000494976
[39]Baek Seol-Hee., Kim Boram., Shin Je-Young., Choi Seok-Jin., Ahn So Hyun., Choi Youn Soo., Kim Sung-Min., Sung Jung-Joon.(2021). EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines. J Neuroimmunol, 358(undefined), 577637. doi:10.1016/j.jneuroim.2021.577637
[40]Pache Florence., Ringelstein Marius., Aktas Orhan., Kleiter Ingo., Jarius Sven., Siebert Nadja., Bellmann-Strobl Judith., Paul Friedemann., Ruprecht Klemens.(2021). C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. J Neuroimmunol, 360(undefined), 577699. doi:10.1016/j.jneuroim.2021.577699